Filed
Pursuant to Rule 424(b)(3) and Rule 424(c)
Registration No. 333-216533
Prospectus
Supplement No. 11
(To Prospectus filed on April 28, 2017, as supplemented
by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus
Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14,
2017, Prospectus Supplement No. 5 dated June 26, 2017, Prospectus Supplement No. 6 dated June 30, 2017, Prospectus Supplement
No. 7 dated August 3, 2017, Prospectus Supplement No. 8 dated August 14, 2017, Prospectus Supplement No. 9 dated August 25, 2017,
and Prospectus Supplement No. 10
dated September 5, 2017)
ENUMERAL
BIOMEDICAL HOLDINGS, INC.
This
Prospectus Supplement No. 11 supplements the information contained in the Prospectus, dated as of April 28, 2017, as supplemented
by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3
dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus Supplement No. 5 dated June 26, 2017, Prospectus
Supplement No. 6 dated June 30, 2017, Prospectus Supplement No. 7 dated August 3, 2017, Prospectus Supplement No. 8 dated August
14, 2017, Prospectus Supplement No. 9 dated August 25, 2017, and Prospectus Supplement No. 10 dated September 5, 2017, relating
to the resale of up to 133,674,598 shares of our common stock by selling stockholders.
This
Prospectus Supplement No. 11 is being filed to include the information set forth in our Current Report on Form 8-K, which was
filed with the Securities and Exchange Commission on September 22, 2017.
You
should read this Prospectus Supplement No. 11 in conjunction with the Prospectus. This Prospectus Supplement No. 11 is qualified
by reference to the Prospectus, except to the extent that the information contained in this Prospectus Supplement No. 11 supersedes
the information contained in the Prospectus. This Prospectus Supplement No. 11 is not complete without, and may not be utilized
except in connection with, the Prospectus.
You
should consider carefully the risks that we have described in “Risk Factors” beginning on page 7 of the Prospectus.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The
date of this Prospectus Supplement is September 22, 2017
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported):
September 19, 2017
Enumeral Biomedical Holdings,
Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
000-55415
|
99-0376434
|
(State or Other Jurisdiction
|
(Commission File
|
(I.R.S. Employer
|
of Incorporation)
|
Number)
|
Identification Number)
|
|
200 CambridgePark Drive,
Suite 2000
|
|
|
|
|
Cambridge, Massachusetts
|
|
|
02140
|
|
(Address of Principal Executive Offices)
|
|
|
(Zip Code)
|
(617) 945-9146
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address,
if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 3.01
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
|
|
On September 19, 2017, Enumeral Biomedical Holdings, Inc.
(the “Company”) received an OTCQB Bid Price Deficiency Notice from OTC Markets (the “Notice”). The Notice
stated that the Company’s bid price had closed below $0.01 for more than 30 consecutive calendar days and no longer met the
Standards for Continued Eligibility for OTCQB as per the OTCQB Standards Section 2.3(2). The Notice also stated that pursuant to
Section 4.1 of the OTCQB Standards, the Company is granted a cure period of 90 calendar days during which the minimum closing bid
price for the Company’s common stock must be $0.01 or greater for ten consecutive trading days in order to continue trading
on the OTCQB marketplace.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ENUMERAL BIOMEDICAL HOLDINGS,
INC.
|
|
|
|
|
|
Dated:
|
September 22, 2017
|
By:
|
/s/
|
Kevin
G. Sarney
|
|
|
|
Name:
|
Kevin G. Sarney
|
|
|
|
Title:
|
Interim Chief Executive Officer and
|
|
|
|
|
President, Vice President of Finance,
|
|
|
|
|
Chief Accounting Officer and
|
|
|
|
|
Treasurer
|